Form D · Biotechnology
Phagos, Inc.
Ivry Sur Seine, I0 · CIK 0001937230
Offering snapshot reported Nov 18, 2024 · SEC filing
- Reported sold
- $0 Offering amount: $7.62M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 18, 2024 | Initial | $0 | No comparison | 13 | SEC filing |
| Sep 15, 2022 | Initial | $1,451,725 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-529675
October 29, 2024 Close: 1 EUR = 1.0819 USD
Source: Form D, filed Nov 18, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Geoffroy Dubus | Director |
| Adele James | Director |
| Robert Kniaz | Director |
| Xin Ma | Director |
| Alexandros Pantalis | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Rue Jean Jacques Rousseau F2 112 5
Ivry Sur Seine, I0, 94200
Ivry Sur Seine, I0, 94200